ProCE Banner Activity

CARES: Long-Acting CAB + RPV in Sub-Saharan Africa

Conference Coverage

At Week 48 analysis of a phase IIIb trial in a sub-Saharan African population, LA CAB + RPV administered IM every 2 months demonstrated noninferior efficacy by FDA snapshot analysis and improved patient satisfaction vs standard-of-care oral ART.

Released: March 06, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare